Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

EKSO has been the subject of a number of other research reports. HC Wainwright decreased their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital decreased their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Performance

EKSO opened at $0.58 on Friday. The company has a market capitalization of $12.76 million, a price-to-earnings ratio of -0.89 and a beta of 1.43. The business’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $1.01. Ekso Bionics has a 1 year low of $0.50 and a 1 year high of $3.13. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. During the same quarter in the previous year, the firm posted ($0.24) EPS. Equities analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.